Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2026)

Recursion Pharmaceuticals' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$18.5 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 30.61% year-over-year to -$18.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $733000.0 (up 133.09% YoY) and the FY2025 annual result came in at -$7.4 million, down 234.21% from the prior year.
• Change in Accured Expenses was -$18.5 million for Q1 2026 at Recursion Pharmaceuticals, down from $15.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.8 million in Q4 2025 and bottomed at -$26.6 million in Q1 2025.
• A 5-year average of -$835058.8 and a median of $2.8 million in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 641.26% in 2022, while the deepest fall reached 11680.0% in 2022.
• Recursion Pharmaceuticals' Change in Accured Expenses stood at $12.2 million in 2022, then slumped by 77.12% to $2.8 million in 2023, then jumped by 278.01% to $10.5 million in 2024, then soared by 50.56% to $15.8 million in 2025, then plunged by 216.49% to -$18.5 million in 2026.
• Business Quant data shows RXRX's Change in Accured Expenses at -$18.5 million in Q1 2026, $15.8 million in Q4 2025, and -$8.0 million in Q3 2025.